Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ploug

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Theranostics|July 12, 2013
Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonistMichael Ploug
Current Pharmaceutical Design|July 23, 2003
Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptorMichael Ploug
Current Opinion in Lipidology|December 3, 2021
ANGPTL4: a new mode in the regulation of intravascular lipolysisMichael Ploug
The Journal of Biological Chemistry|March 16, 2007
Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker regionHenrik Gårdsvoll, Michael Ploug
Frontiers in Cell and Developmental Biology|September 7, 2021
Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic InterventionJulie Maja Leth, Michael Ploug
Methods in Molecular Biology (Clifton, N.J.)|July 23, 2020
Determination of Binding Kinetics of Intrinsically Disordered Proteins by Surface Plasmon ResonanceJulie M Leth, Michael Ploug
Current Pharmaceutical Design|July 29, 2004
The urokinase receptor as a potential target in cancer therapyJohn Romer, Boye Schnack Nielsen, Michael Ploug
Cancers|November 13, 2021
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and OpportunitiesVirginia Metrangolo, Michael Ploug, Lars H Engelholm
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|February 23, 2011
Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesisMette C Kriegbaum, Benedikte Jacobsen, Andreas Hald, et al.
The Journal of Biological Chemistry|February 6, 2010
Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapyLin Lin, Henrik Gårdsvoll, Qing Huai, et al.
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Theranostics|July 12, 2013
Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonistMichael Ploug
Current Pharmaceutical Design|July 23, 2003
Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptorMichael Ploug
Current Opinion in Lipidology|December 3, 2021
ANGPTL4: a new mode in the regulation of intravascular lipolysisMichael Ploug
The Journal of Biological Chemistry|March 16, 2007
Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker regionHenrik Gårdsvoll, Michael Ploug
Frontiers in Cell and Developmental Biology|September 7, 2021
Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic InterventionJulie Maja Leth, Michael Ploug
Methods in Molecular Biology (Clifton, N.J.)|July 23, 2020
Determination of Binding Kinetics of Intrinsically Disordered Proteins by Surface Plasmon ResonanceJulie M Leth, Michael Ploug
Current Pharmaceutical Design|July 29, 2004
The urokinase receptor as a potential target in cancer therapyJohn Romer, Boye Schnack Nielsen, Michael Ploug
Cancers|November 13, 2021
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and OpportunitiesVirginia Metrangolo, Michael Ploug, Lars H Engelholm
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|February 23, 2011
Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesisMette C Kriegbaum, Benedikte Jacobsen, Andreas Hald, et al.
The Journal of Biological Chemistry|February 6, 2010
Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapyLin Lin, Henrik Gårdsvoll, Qing Huai, et al.
Pageof 13